Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "fc points apple pay Buyfc26coins.com is FC 26 coins official site..1Z6B"

Looking for quality documents?
external link icon
Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions
Proposed A RTeSYN a cquisition adds gold standard single - use downstream bioprocessing s ystems
Advances Repligen’s S ystems strategy in Filtration and Chromatography , c omplement ing TangenX ® F lat S heet cassettes and OPUS ® PP C Completes acquisition of Non-Metallic Solutions (NMS), complementing our recent acquisition of EMT and further strengthens our single-use flow paths, durable plastics and assembly portfolio
WALTHAM, Mass., Oct. 27, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held ARTeSYN Biosolutions (“ARTeSYN”) for approximately $200 million, comprised of approximately $130 million in cash and approximately $70 million in Repligen common stock. ARTeSYN Biosolutions is projected to generate approximately $30 million in revenue (pro forma) in 2020, led by the success of its
external link icon
Repligen Corporation Announces Closing of Public Offerings of $138.1 Million of Common Stock and $287.5 Million of 0.375% Convertible Senior Notes due 2024, Including Full Exercise of Underwriters’ Options
WALTHAM, Mass., July 19, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced the closing of its previously announced concurrent underwritten public offerings of an aggregate of 1,587,000 shares of its common stock (the “Shares”) at a public offering price of $87.00 per share for gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, of approximately $138.1 million, and $287.5 million aggregate principal amount of 0.375% Convertible Senior Notes due 2024 (the “Notes”), which includes the exercise in full of the underwriters’ option to purchase 207,000 additional Shares and $37.5 million additional Notes. The offering of the Shares (the “Shares Offering”) is expected to result in approximately $130.7 million in net proceeds to Repligen after deducting underwriting discounts and commissions and other estimated offering expenses payable by Repligen. The offering of the Notes (the “Notes Offering” and,
video icon
Biologics concentration measurement with the FlowVPX during the UF/DF process in drug substance mftg (Bristol-Myers Squibb)
The FlowVPX System was used as an in-line instrument for product concentration measurement during UF/DF operations, with orthogonal offline testing done to check comparability. The FlowVPX device has generated significant interest for high concentration UF/DF processes in particular (less than 150 g/L) since overconcentration can result in precipitation. The FlowVPX System has significant potential for GMP and commercial biologics manufacturing with the development of single use flow cells by the vendor. Extensive testing was done using small and pilot scale UF/DF operations with several biologic drugs molecules from the company’s portfolio.  The FlowVPX instrument demonstrated acceptable comparability (within 5% difference) with orthogonal A280 based protein concentration measurements for all molecules tested. Accuracy and precision were equivalent for all flow cells and scales tested, suggesting the FlowVPX can be a robust reliable in-line instrument in GMP settings. Speaker: Jay West, Ph.D., Principal Scientist Biologics Process Development – BMS.
external link icon
Repligen Reports Third Quarter 2012 Financial Results
Repligen Corporation (NASDAQ: RGEN) today reported financial results for its third quarter and year-to-date period ended September 30, 2012. The Company reported net income for the three-month period ended September 30, 2012 of $1,806,000 or $0.06 per diluted share, compared to $605,000 or $0.02 per diluted share for the same period in 2011, an increase of 199%. Total revenue for the three-month period ended September 30, 2012 was $15,104,000 compared to $8,631,000 for the same period in 2011, an increase of 75%. Revenue growth for the third quarter of 2012 was driven by the Company’s expanded bioprocessing business, which generated $11,123,000 in product revenue compared to $5,742,000 for the same period in 2011, an increase of 94%. Royalty and research revenue for the three-month period ended September 30, 2012, consisting primarily of royalty payments from Bristol-Myers Squibb on its U.S. sales of Orencia ® , was $3,981,000 compared to $2,889,000 for the same period in 2011.
publications icon
Validating Protein Concentration of Antibody-Drug Conjugates with the CTech™ SoloVPE® System
 UV-Vis spectroscopy is the simplest and most common method to determine protein concentration of ADCs; however, traditional fixed-pathlength spectrophotometers have issues. Authors: Nigel Herbert, Joshua Das, Priya Patel-Abbvie
external link icon
Repligen Announces Strategic Focus on Bioprocessing Business and Reports Second Quarter 2012 Financial Results
Repligen Corporation (NASDAQ: RGEN) today reported financial results for its second quarter and year-to-date period ended June 30, 2012. In addition, the Company announced that it will focus its corporate strategy and resources on the growth of its core bioprocessing business, which achieved record sales during the quarter. As a result of this defined strategic focus, the Company will seek a development and commercialization partner for its pancreatic imaging product candidate, RG1068. The Company reported total revenue for the three-month period ended June 30, 2012 of $15,524,000 compared to $7,654,000 for the same period in 2011. Revenue growth for the second quarter of 2012 was driven by the Company’s expanded bioprocessing business, which generated $11,659,000 in product revenue compared to $4,358,000 for the same period in 2011, an increase of 168%. Royalty and research revenue for the three-month period ended June 30, 2012, consisting primarily of royalty payments from
external link icon
Repligen Reports First Quarter 2015 Financial Results
- Product Sales Increase 45% to a Record $20.8 Million -

- Conference Call and Webcast Today at 8:30 a.m. EDT - WALTHAM, Mass., May 7, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today reported financial results for the first quarter ended March 31, 2015. Below are the Company’s performance highlights for the quarter, followed by updated financial guidance for the year 2015 and access information for today’s webcast and conference call. First Quarter Financial Highlights   Bioprocessing product revenue for the first quarter of 2015 was $20.8 million, compared to $14.3 million for the first quarter of 2014, an increase of 45% including a negative impact of 12% from foreign currency translation. Total revenue for the first quarter of 2015 was comprised entirely of bioprocessing product revenue, while during the first quarter of 2014, total revenue of $16.3 million included a one-time upfront payment of $2.0 million from BioMarin Pharmaceutical Inc. under
external link icon
Repligen Announces Acquisition of Chromatography Technology Platform "Plug and Play" Products Create Broad Opportunity in Biopharmaceutical Manufacturing
external link icon
Repligen Reports Third Quarter 2017 Financial Results
Record quarterly revenue of $36.6 million represents 48% year-over-year growth
Year-to-date revenue of $99.6 million represents 26% year-over-year growth Spectrum contributes revenue of $7.6 million in first two months of ownership WALTHAM, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter ended September 30, 2017. Detailed in this press release are the Company's performance highlights for the quarter, followed by updated financial guidance for the year 2017 and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said “I’m very pleased with our overall performance in the third quarter. We closed on the Spectrum acquisition in August and our new colleagues delivered terrific results, with greater than 30% year-on-year revenue growth for the first two months of ownership.
external link icon
Repligen Launches OPUS(R) Ready-to-Use Chromatography Columns With Largest Capacity Available on the Market
WALTHAM, Mass., March 26, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN), a technology leader in pre-packed columns for the cost-effective purification of biologic drugs, today announced the commercial launch of its OPUS ® 45 cm diameter columns ("OPUS 45") with the largest capacity currently available on the market. OPUS columns, which now range from 1.2 cm to 45 cm in diameter, are delivered packed with chromatography media used to purify monoclonal antibodies and other biologic drugs. OPUS technology increases facility flexibility, improves the speed of process development and reduces the cost of biopharmaceutical manufacturing by decreasing the set-up, cleaning and validation times associated with traditional purification technologies. OPUS 45 was designed to process large single-use bioreactor harvests and will be formally launched at Biopharmaceutical Development & Production Week being held March 24-27 at the Hilton Bayfront Hotel in San Diego. "Since launching
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support